BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 12678912)

  • 1. Structure-based design of novel anti-cancer agents targeting aurora kinases.
    Mahadevan D; Bearss DJ; Vankayalapati H
    Curr Med Chem Anticancer Agents; 2003 Jan; 3(1):25-34. PubMed ID: 12678912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting aurora2 kinase in oncogenesis: a structural bioinformatics approach to target validation and rational drug design.
    Vankayalapati H; Bearss DJ; Saldanha JW; Muñoz RM; Rojanala S; Von Hoff DD; Mahadevan D
    Mol Cancer Ther; 2003 Mar; 2(3):283-94. PubMed ID: 12657723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polo and Aurora kinases: lessons derived from chemical biology.
    Taylor S; Peters JM
    Curr Opin Cell Biol; 2008 Feb; 20(1):77-84. PubMed ID: 18249108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress in the development of selective inhibitors of Aurora kinases.
    Mortlock A; Keen NJ; Jung FH; Heron NM; Foote KM; Wilkinson R; Green S
    Curr Top Med Chem; 2005; 5(2):199-213. PubMed ID: 15853647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress in the development of selective inhibitors of aurora kinases.
    Mortlock AA; Keen NJ; Jung FH; Heron NM; Foote KM; Wilkinson RW; Green S
    Curr Top Med Chem; 2005; 5(8):807-21. PubMed ID: 16101420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aurora-B kinase inhibitors for cancer chemotherapy.
    Yeung SC; Gully C; Lee MH
    Mini Rev Med Chem; 2008 Dec; 8(14):1514-25. PubMed ID: 19075809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shared and separate functions of polo-like kinases and aurora kinases in cancer.
    Lens SM; Voest EE; Medema RH
    Nat Rev Cancer; 2010 Dec; 10(12):825-41. PubMed ID: 21102634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on aurora kinase inhibitors in gynecologic malignancies.
    Tao X; Chon HS; Fu S; Kavanagh JJ; Hu W
    Recent Pat Anticancer Drug Discov; 2008 Nov; 3(3):162-77. PubMed ID: 18991785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aurora kinases.
    Bolanos-Garcia VM
    Int J Biochem Cell Biol; 2005 Aug; 37(8):1572-7. PubMed ID: 15896667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tubulin-associated proteins: Aurora and Polo-like kinases as therapeutic targets in cancer.
    Warner SL; Stephens BJ; Von Hoff DD
    Curr Oncol Rep; 2008 Mar; 10(2):122-9. PubMed ID: 18377825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-inhibition of polo-like kinase 1 and Aurora kinases promotes mitotic catastrophe.
    Li J; Hong MJ; Chow JP; Man WY; Mak JP; Ma HT; Poon RY
    Oncotarget; 2015 Apr; 6(11):9327-40. PubMed ID: 25871386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitotic kinases: the key to duplication, segregation, and cytokinesis errors, chromosomal instability, and oncogenesis.
    Li JJ; Li SA
    Pharmacol Ther; 2006 Sep; 111(3):974-84. PubMed ID: 16603252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-throughput screening assay for identification of small molecule inhibitors of Aurora2/STK15 kinase.
    Sun C; Newbatt Y; Douglas L; Workman P; Aherne W; Linardopoulos S
    J Biomol Screen; 2004 Aug; 9(5):391-7. PubMed ID: 15296638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The serine/threonine kinases that control cell cycle progression as therapeutic targets].
    Diallo A; Prigent C
    Bull Cancer; 2011 Nov; 98(11):1335-45. PubMed ID: 22020767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth suppression and mitotic defect induced by JNJ-7706621, an inhibitor of cyclin-dependent kinases and aurora kinases.
    Matsuhashi A; Ohno T; Kimura M; Hara A; Saio M; Nagano A; Kawai G; Saitou M; Takigami I; Yamada K; Okano Y; Shimizu K
    Curr Cancer Drug Targets; 2012 Jul; 12(6):625-39. PubMed ID: 22463590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting aurora kinases in cancer treatment.
    Kelly KR; Ecsedy J; Mahalingam D; Nawrocki ST; Padmanabhan S; Giles FJ; Carew JS
    Curr Drug Targets; 2011 Dec; 12(14):2067-78. PubMed ID: 21777198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually high selectivity against Aurora B.
    Aliagas-Martin I; Burdick D; Corson L; Dotson J; Drummond J; Fields C; Huang OW; Hunsaker T; Kleinheinz T; Krueger E; Liang J; Moffat J; Phillips G; Pulk R; Rawson TE; Ultsch M; Walker L; Wiesmann C; Zhang B; Zhu BY; Cochran AG
    J Med Chem; 2009 May; 52(10):3300-7. PubMed ID: 19402633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aurora kinases as an anti-cancer target.
    Ikezoe T
    Cancer Lett; 2008 Apr; 262(1):1-9. PubMed ID: 18294763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aurora kinase inhibitors as potential anticancer agents: Recent advances.
    Pradhan T; Gupta O; Singh G; Monga V
    Eur J Med Chem; 2021 Oct; 221():113495. PubMed ID: 34020340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aurora B: a new prognostic marker and therapeutic target in cancer.
    Portella G; Passaro C; Chieffi P
    Curr Med Chem; 2011; 18(4):482-96. PubMed ID: 21143115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.